, Volume 70, Issue 6, pp 1509–1518 | Cite as

Antiproliferative effect of upregulation of hsa-let-7c-5p in human acute erythroleukemia cells

  • Deniz Mortazavi
  • Mohammadreza SharifiEmail author


New achievements in the field of cancer treatment are results of recent advances in molecular medicine and gene therapy. Usage of microRNAs (miRNAs) which are small noncoding RNAs is one of the molecular research lines for the diagnosis and treatment of cancers. miRNAs have an important role in post-transcriptional regulation of the gene expression and are involved in cellular activities such as growth, differentiation, cell death and cancer development. One of the miRNAs that showed downregulation in human acute erythroleukemia is hsa-let-7c-5p. Down-regulation of hsa-let-7c-5p has been reported in in vitro studies of different cancers. In the present study, upregulation of hsa-let-7c-5p is performed in human acute erythroleukemia cell line (KG-1) using miRNA mimic. qRT-PCR, MTT assay, Annexin-V, and propidium iodide staining at different time points after miRNA mimic transfection were accomplished to assess the expression level of hsa-let-7c-5p, cell viability, apoptosis and late apoptosis. In addition, the expression level of PBX2 oncogene, a validated target gene of hsa-let-7c-5p, is evaluated by RT-qPCR to show the effectivity of this approach on erythroleukemia cancer cells. Our results can be used in translational medicine for future investigation in acute erythroleukemia and to approach treatment based on miRNA mimic therapy.


Erythroleukemia hsa-let-7c-5p miRNA mimic Proliferation Apoptosis 



This study was conducted with the financial support of Isfahan University of Medical Sciences (IRAN) with Grant Number 395207.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study was approved by the local ethics committee of Isfahan University of Medical Sciences (IRAN) and the studies have been approved by the appropriate institutional and/or national research ethics committee and have been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.


  1. Acevedo-Olvera LF, Diaz-Garcia H, Parra-Barrera A, Caceres-Perez AA, Gutierrez-Iglesias G, Rangel-Corona R, Caceres-Cortes JR (2015) Inhibition of the Na +/H + antiporter induces cell death in TF-1 erythroleukemia cells stimulated by the stem cell factor. Cytokine 75:142–150CrossRefGoogle Scholar
  2. Amini-Farsani Z, Sangtarash MH, Shamsara M, Teimori H (2018) MiR-221/222 promote chemoresistance to cisplatin in ovarian cancer cells by targeting PTEN/PI3K/AKT signaling pathway. Cytotechnology 70:203–213CrossRefGoogle Scholar
  3. Bader AG, Brown D, Winkler M (2010) The promise of microRNA replacement therapy. Cancer Res 70:7027–7030CrossRefGoogle Scholar
  4. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297CrossRefGoogle Scholar
  5. Byrd JC et al (2004) Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv (16)(p13q22) or t (16; 16)(p13; q22): results from CALGB 8461. J Clin Oncol 22:1087–1094CrossRefGoogle Scholar
  6. Döhner H, Estey EH, Amadori S et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453–474CrossRefGoogle Scholar
  7. Döhner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373:1136–1152CrossRefGoogle Scholar
  8. Döhner H et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424–447CrossRefGoogle Scholar
  9. Dong C, Ji M, Ji C (2009) Micro-RNAs and their potential target genes in leukemia pathogenesis. Cancer Biol Ther 8:200–205CrossRefGoogle Scholar
  10. Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM (2011) Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood 119:34–43CrossRefGoogle Scholar
  11. Drakaki A, Iliopoulos D (2009) MicroRNA gene networks in oncogenesis. Curr Genom 10:35–41CrossRefGoogle Scholar
  12. Faller M, Guo F (2008) MicroRNA biogenesis: there’s more than one way to skin a cat. Biochim Biophys Acta BBA Gene Regul Mech 1779:663–667CrossRefGoogle Scholar
  13. Gambari R, Brognara E, Spandidos DA, Fabbri E (2016) Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology. Int J Oncol 49:5–32CrossRefGoogle Scholar
  14. Gammell P (2007) MicroRNAs: recently discovered key regulators of proliferation and apoptosis in animal cells. Cytotechnology 53:55–63CrossRefGoogle Scholar
  15. George G, Mittal RD (2010) MicroRNAs: potential biomarkers in cancer. Indian J Clin Biochem 25:4–14CrossRefGoogle Scholar
  16. Gong C et al (2011) Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 286:19127–19137CrossRefGoogle Scholar
  17. Han H, Gu J, Zuo H et al (2012) Let-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer. J Pathol 226:544–555CrossRefGoogle Scholar
  18. Hasserjian R, Howard J, Wood A, Henry K, Bain B (2001) Acute erythremic myelosis (true erythroleukaemia): a variant of AML FAB-M6. J Clin Pathol 54:205–209CrossRefGoogle Scholar
  19. Hertel J, Bartschat S, Wintsche A, Otto C, of the Bioinformatics Computer Lab TS, Stadler PF (2012) Evolution of the let-7 microRNA family. RNA Biol 9:231–241CrossRefGoogle Scholar
  20. Johnson SM et al (2005) RAS is regulated by the let-7 microRNA family. Cell 120:635–647CrossRefGoogle Scholar
  21. Johnson CD et al (2007) The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67:7713–7722CrossRefGoogle Scholar
  22. Kavianpour M, Ahmadzadeh A, Shahrabi S, Saki N (2016) Significance of oncogenes and tumor suppressor genes in AML prognosis. Tumor Biol 37:10041–10052CrossRefGoogle Scholar
  23. Kloosterman WP, Plasterk RH (2006) The diverse functions of microRNAs in animal development and disease. Dev Cell 11:441–450CrossRefGoogle Scholar
  24. Kowal-Vern A, Mazzella FM, Cotelingam JD, Shrit MA, Rector JT, Schumacher HR (2000) Diagnosis and characterization of acute erythroleukemia subsets by determining the percentages of myeloblasts and proerythroblasts in 69 cases. Am J Hematol 65:5–13CrossRefGoogle Scholar
  25. Liu L et al (2017) MicroRNA-29c functions as a tumor suppressor by targeting VEGFA in lung adenocarcinoma. Mol Cancer 16:50CrossRefGoogle Scholar
  26. Marcucci G, Mrózek K, Bloomfield CD (2005) Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol 12:68–75CrossRefGoogle Scholar
  27. Mazzella FM, Alvares C, Kowal-Vern A, Schumacher HR (2000) The acute erythroleukemias. Clin Lab Med 20:119–137CrossRefGoogle Scholar
  28. Mohammadiasl J, Khosravi A, Shahjahani M, Azizidoost S, Saki N (2016) Molecular and cellular aspects of extramedullary manifestations of acute myeloid leukemia. J Cancer Metastasis Treat 2:44–50Google Scholar
  29. Monica K, Galili N, Nourse J, Saltman D, Cleary ML (1991) PBX2 and PBX3, new homeobox genes with extensive homology to the human proto-oncogene PBX1. Mol Cell Biol 11:6149–6157CrossRefGoogle Scholar
  30. Moskow JJ, Bullrich F, Huebner K, Daar IO, Buchberg AM (1995) Meis1, a PBX1-related homeobox gene involved in myeloid leukemia in BXH-2 mice. Mol Cell Biol 15:5434–5443CrossRefGoogle Scholar
  31. Nadiminty N et al (2012) MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS ONE 7:e32832CrossRefGoogle Scholar
  32. Park S-M et al (2007) Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 6:2585–2590CrossRefGoogle Scholar
  33. Pelosi A et al (2013) miRNA let-7c promotes granulocytic differentiation in acute myeloid leukemia. Oncogene 32:3648–3654CrossRefGoogle Scholar
  34. Reddy SDN, Gajula RP, Pakala SB, Kumar R (2010) MicroRNAs and cancer therapy: the next wave or here to stay? Cancer Biol Ther 9:479–482CrossRefGoogle Scholar
  35. Rothschild SI (2014) microRNA therapies in cancer. Mol Cell Ther 2:7CrossRefGoogle Scholar
  36. Rowley JD (2008) Chromosomal translocations: revisited yet again. Blood 112:2183–2189CrossRefGoogle Scholar
  37. Ruan K, Fang X, Ouyang G (2009) MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 285:116–126CrossRefGoogle Scholar
  38. Santos F et al (2009) Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia 23:2275–2280CrossRefGoogle Scholar
  39. Sarver AL, Li L, Subramanian S (2010) MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Res 70:9570–9580CrossRefGoogle Scholar
  40. Sharifi M, Salehi R, Gheisari Y, Kazemi M (2014) Inhibition of microRNA miR-92a induces apoptosis and inhibits cell proliferation in human acute promyelocytic leukemia through modulation of p63 expression. Mol Biol Rep 41:2799–2808CrossRefGoogle Scholar
  41. Shen W-F, Rozenfeld S, Kwong A, Kömüves LG, Lawrence HJ, Largman C (1999) HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells. Mol Cell Biol 19:3051–3061CrossRefGoogle Scholar
  42. Shi Y, Liu C, Liu X, Tang DG, Wang J (2014) The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells. PLoS ONE 9:e90022CrossRefGoogle Scholar
  43. Stoicea N, Du A, Lakis DC, Tipton C, Arias-Morales CE, Bergese SD (2016) The MiRNA journey from theory to practice as a CNS biomarker. Front Genet 7:11CrossRefGoogle Scholar
  44. Tenen DG (2003) Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 3:89–101CrossRefGoogle Scholar
  45. Yuan Y, Kasar S, Underbayev C, Prakash S, Raveche E (2012) MicroRNAs in acute myeloid leukemia and other blood disorders. Leuk Res Treat 2012:603830. CrossRefGoogle Scholar
  46. Zhao B et al (2014) MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3. Cancer Lett 342:43–51CrossRefGoogle Scholar
  47. Zhu X, Wu L, Yao J, Jiang H, Wang Q, Yang Z, Wu F (2015) MicroRNA let-7c inhibits cell proliferation and induces cell cycle arrest by targeting CDC25A in human hepatocellular carcinoma. PLoS ONE 10:e0124266CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  1. 1.Department of Genetics and Molecular Biology, School of MedicineIsfahan University of Medical ScienceIsfahanIran

Personalised recommendations